+1,422.9%
KLAC vs MRNA
+786.4%
+636.5%
-57.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -10.3% | -2.2% | -8.2% | -10.2% |
| 7D | -16.6% | -12.7% | -3.9% | -15.8% |
| 30D | -22.3% | -20.7% | -1.6% | -21.1% |
| 3M | -31.6% | +46.3% | -77.9% | -33.4% |
| 6M | -30.5% | +305.2% | -335.7% | -41.9% |
| YTD | +5.0% | +561.2% | -556.3% | -18.0% |
| 1Y | +15.7% | +772.1% | -756.4% | -12.8% |
| 3Y | +132.7% | +147.0% | -14.3% | +95.8% |
| 5Y | +215.0% | -26.1% | +241.1% | +185.1% |
| All | +1,422.9% | +786.4% | +636.5% | +1,171.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling